Search | Clinical Trials Finder

Conditions: Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 760
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more

Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions: dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method; Drug · Other · Genetic
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 17
States / cities: Alhambra, California • Fullerton, California • Long Beach, California + 12 more

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
Interventions: BMS-986500, Palbociclib, Fulvestrant; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Fullerton, California • Greenbrae, California + 11 more

Conditions: Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions: arformoterol tartrate inhalation solution, Salmeterol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 65
States / cities: Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Diabetes Mellitus Type 2
Interventions: Aleglitazar, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 7,226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 221
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more

Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma
Interventions: Talazoparib, Temozolomide; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 6
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more

Conditions: Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 798
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more

Conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions: Donanemab, Aducanumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Durvalumab, Laboratory Biomarker Analysis, Tremelimumab; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1021
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 110
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more

Conditions: Ovarian Cancer
Interventions: INCB123667, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 63
States / cities: Anchorage, Alaska • Tucson, Arizona • Duarte, California + 56 more

Conditions: Amblyopia
Interventions: Patching, Glasses; Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 3 Years to 13 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 68
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 57 more

Conditions: Breast Ductal Carcinoma In Situ
Interventions: Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation; Other · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 2,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 1249
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 764 more

Conditions: Breast Neoplasms
Interventions: PD-0332991, Letrozole, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 136
States / cities: Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 429
States / cities: Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel, pemetrexed; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 32
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Pancreatic Cancer
Interventions: Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 30
States / cities: Tucson, Arizona • Burbank, California • Cerritos, California + 26 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ublituximab, Ibrutinib; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 87
States / cities: Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 81 more

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 886 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 227
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more

Conditions: Acne Vulgaris
Interventions: Olumacostat Glasaretil Gel, 5.0%; Drug
Lead sponsor: Dermira, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 73
States / cities: Guntersville, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Asthma
Interventions: lebrikizumab, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 70
States / cities: Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more

Search by objective public record fields.

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)